What Is 3-FPM

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-FPM (3-Fluorophenmetrazine) is a synthetic stimulant drug of the phenylmorpholine class, first identified in 2014. It acts as a norepinephrine-dopamine releasing agent and is often sold as a research chemical.

Key Facts

3-FPM was first detected in European drug markets in 2014
It is a structural analog of phenmetrazine, a former prescription weight-loss drug
3-FPM increases dopamine and norepinephrine release in the brain
It has been banned in several countries including the UK and Germany
Limited human studies exist; most data come from animal research and user reports

Overview

3-FPM, or 3-Fluorophenmetrazine, is a synthetic stimulant belonging to the phenylmorpholine class of compounds. It emerged as a designer drug in the early 2010s and is often marketed as a 'research chemical' to circumvent drug laws.

Originally developed for scientific study, 3-FPM has gained notoriety in recreational drug communities due to its stimulant effects. It is structurally similar to older pharmaceuticals like phenmetrazine, which was once prescribed for obesity but withdrawn due to abuse potential.

Chemical class: 3-FPM is classified as a substituted phenylmorpholine, sharing core structural features with stimulants like phendimetrazine and norephedrine.
First detection: It was first identified in European forensic labs in 2014, signaling its emergence in illicit drug markets.
Molecular weight: The compound has a molecular weight of 223.28 g/mol, with the chemical formula C11H14FNO.
Legal status: As of 2023, 3-FPM is controlled in the UK under the Psychoactive Substances Act and in Germany under the NpSG.
Availability: It is commonly sold online through gray-market vendors, often labeled 'not for human consumption' to avoid regulation.

How It Works

3-FPM exerts its effects primarily through the central nervous system by influencing monoamine neurotransmitters. Its mechanism closely resembles that of other stimulants, though with distinct pharmacological nuances.

Dopamine release:Studies show 3-FPM induces dopamine release with an EC50 value of approximately 240 nM, contributing to its euphoric and reinforcing effects.
Norepinephrine activity: It has a higher potency for norepinephrine release, with an EC50 of 180 nM, leading to increased alertness and physical stimulation.
Serotonin interaction: Unlike MDMA or mephedrone, 3-FPM has minimal effect on serotonin, reducing hallucinogenic potential but increasing stimulant risks.
Duration of action: User reports suggest effects last between 4 to 6 hours, depending on dosage and route of administration.
Metabolism: It is metabolized in the liver, primarily via dealkylation and hydroxylation, though full metabolic pathways are not fully mapped.
Addiction potential: Animal studies indicate moderate to high self-administration rates, suggesting significant abuse liability.

Comparison at a Glance

Below is a comparison of 3-FPM with related stimulant compounds based on pharmacology, legal status, and effects.

Compound	Dopamine EC50 (nM)	Norepinephrine EC50 (nM)	Legal Status (EU)	Typical Dose (oral)
3-FPM	240	180	Banned in multiple countries	50–150 mg
Phenmetrazine	320	210	Prescription-only (historical)	75–100 mg
Methylphenidate	200	150	Prescription-only	10–30 mg
4-FMA	280	190	Banned in EU	50–100 mg
Cocaine	140	120	Illegal	30–100 mg (nasal)

The table highlights that 3-FPM is less potent than cocaine in dopamine release but more selective than some analogs. Its legal status varies widely, but increasing regulation reflects growing concern over public health risks. While structurally similar to older pharmaceuticals, its unregulated nature raises safety concerns.

Why It Matters

Understanding 3-FPM is crucial due to its rising presence in recreational drug use and the lack of clinical safety data. Its availability online poses challenges for public health monitoring and law enforcement.

Public health risk: The absence of quality control in gray-market products increases the risk of overdose or contamination.
Emergency cases: Hospitals in the UK reported over 20 cases of 3-FPM-related toxicity between 2018 and 2021.
Legal loopholes: Vendors exploit research chemical labeling to avoid prosecution despite known harms.
Youth exposure: Online availability makes it accessible to teens and young adults experimenting with stimulants.
Research value: Despite risks, 3-FPM is studied to understand monoamine transporter function in neuroscience.
Policy impact: Its emergence has prompted countries to adopt generic drug bans targeting entire chemical classes.

As synthetic stimulants evolve, monitoring compounds like 3-FPM becomes essential for harm reduction and regulatory strategy. Public awareness and forensic surveillance play key roles in mitigating potential abuse.